Gilead Sciences +

Gilead Sciences

Company

Ticker

GILD

LLY

JNJ

ABBV

Headquarter

Foster City ,CA

Indianapolis ,IN

New Brunswick ,NJ

North Chicago ,IL

CEO

Daniel O'Day

David A. Ricks

Joaquin Duato

Robert A. Michael

Industry

Drug Manufacturers - General

Stock Price

Market Cap

$175.40 B

$867.07 B

$571.82 B

$368.38 B

Employees

Years

2024
2025
2026

2024
2025
2026

2024
2025
2026

2024
2025
2026

Employees

18.00 K
17.60 K
17.00 K

43.00 K
47.00 K
50.00 K

131.90 K
138.10 K
138.20 K

50.00 K
55.00 K
57.00 K

Y/Y

5.88%

2.22%

3.41%

10.26%

9.3%

6.38%

13.62%

4.7%

0.07%

10%

3.64%

Income Statement

Revenue

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Revenue

$27.12 B
$28.75 B
$29.44 B

$34.12 B
$45.04 B
$65.18 B

$85.16 B
$88.82 B
$94.19 B

$54.32 B
$56.33 B
$61.16 B

Y/Y

0.6%

6.04%

2.4%

19.56%

32%

44.7%

6.46%

4.3%

6.05%

6.44%

3.71%

8.57%

Revenue by Products / Services

Years

2025

2025

2025

2025

Revenue by Geography

Years

2025

2025

2025

2025

Research and Development

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Research and Development

$5.72 B
$5.91 B
$5.69 B

$9.31 B
$10.99 B
$13.34 B

$15.09 B
$17.23 B
$14.67 B

$7.68 B
$12.79 B
$9.10 B

Y/Y

14.89%

3.31%

3.72%

29.52%

18.01%

21.35%

6.72%

14.23%

14.9%

17.9%

66.66%

28.89%

Operating Income

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Operating Income

$7.61 B
$1.66 B
$11.82 B

$10.79 B
$17.50 B
$29.70 B

$23.41 B
$22.15 B
$25.60 B

$12.76 B
$9.14 B
$21.21 B

Y/Y

3.75%

78.15%

611.01%

24.66%

62.24%

69.67%

11.4%

5.38%

15.56%

29.59%

28.38%

132.18%

Tax Rate (%)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Tax Rate (%)

18.18%
30.58%
13.13%

20.05%
16.49%
19.79%

11.53%
15.71%
17.73%

22.03%
-15.34%
35.83%

Y/Y

15.3%

68.2%

57.07%

143%

17.78%

20.04%

25.35%

36.28%

12.89%

81.94%

169.62%

333.62%

Net Income

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Net Income

$5.67 B
$480.00 M
$8.51 B

$5.24 B
$10.59 B
$20.64 B

$35.15 B
$14.07 B
$26.80 B

$4.86 B
$4.28 B
$4.23 B

Y/Y

23.37%

91.53%

1672.92%

16.08%

102.08%

94.88%

95.94%

59.99%

90.56%

58.91%

12.03%

1.22%

Revenue Per Employee

Years

2024
2025
2026

2024
2025
2026

2024
2025
2026

2024
2025
2026

Revenue Per Employee

$1.60 M
$1.67 M
-

$1.05 M
$1.39 M
-

$673.40 K
$682.06 K
-

$1.13 M
$1.11 M
-

Y/Y

0.15%

4.72%

100%

19.72%

32.39%

100%

20.75%

1.29%

100%

3.71%

1.3%

100%

Net Income Per Employee

Years

2024
2025
2026

2024
2025
2026

2024
2025
2026

2024
2025
2026

Net Income Per Employee

$26.67 K
$483.52 K
-

$246.28 K
$439.11 K
-

$106.64 K
$194.09 K
-

$85.56 K
$76.84 K
-

Y/Y

92%

1713.21%

100%

83.29%

78.3%

100%

53.68%

82%

100%

12.03%

10.2%

100%

Assets & Liabilities | Cash Flow

Total Assets

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Total Assets

$62.13 B
$59.00 B
$59.02 B

$64.01 B
$78.71 B
$112.48 B

$167.56 B
$180.10 B
$199.21 B

$134.71 B
$135.16 B
$5.46 B

Y/Y

1.66%

5.04%

0.05%

29.33%

22.98%

42.89%

10.58%

7.49%

10.61%

2.95%

0.33%

95.96%

Total Liabilities

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Total Liabilities

$39.38 B
$39.75 B
$36.41 B

$53.14 B
$64.44 B
$85.94 B

$98.78 B
$108.61 B
$117.67 B

$124.31 B
$131.80 B
$26.29 B

Y/Y

6.16%

0.95%

8.41%

37.27%

21.26%

33.36%

10.66%

9.95%

8.33%

2.3%

6.02%

80.05%

Capital Expenditures (Capex)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Capital Expenditures (Capex)

-$585.00 M
-$523.00 M
-

-$7.39 B
-$8.40 B
-$7.84 B

-$4.54 B
-$4.42 B
-$4.83 B

-$777.00 M
-$974.00 M
-

Y/Y

19.64%

10.6%

100%

147.62%

13.68%

6.69%

13.32%

2.62%

9.22%

11.8%

25.35%

100%

Profitability

Operating Income Margin (%)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Operating Income Margin (%)

28.05%
5.78%
40.14%

31.61%
38.86%
45.56%

27.49%
24.94%
27.17%

23.49%
16.22%
34.69%

Y/Y

4.38%

79.39%

594.37%

4.27%

22.91%

17.26%

4.64%

9.28%

8.97%

24.74%

30.94%

113.86%

Net Income Margin (%)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Net Income Margin (%)

20.89%
1.67%
28.90%

15.36%
23.51%
31.66%

41.28%
15.84%
28.46%

8.95%
7.59%
6.91%

Y/Y

24.12%

92.01%

1631.43%

29.81%

53.1%

34.68%

84.04%

61.64%

79.69%

56.09%

15.18%

9.01%

EBITDA

2022	8852000000.00
2023	10496000000.00
2024	4434000000.00
2025	10820000000.00

2022	8660500000.00
2023	8567800000.00
2024	15227600000.00
2025	27936500000.00

2022	26605000000.00
2023	23320000000.00
2024	24781000000.00
2025	32581000000.00

2022	24174000000.00
2023	17172000000.00
2024	14910000000.00
2025	28293665000.00

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

EBITDA

$10.50 B
$4.43 B
$10.82 B

$8.57 B
$15.23 B
$27.94 B

$23.32 B
$24.78 B
$32.58 B

$17.17 B
$14.91 B
$28.29 B

Y/Y

18.57%

57.76%

144.02%

1.07%

77.73%

83.46%

12.35%

6.27%

31.48%

28.97%

13.17%

89.76%

Free Cash Flow (FCF)

2022	8344000000.00
2023	7421000000.00
2024	10305000000.00
2025	10019000000.00

2022	4600400000.00
2023	-3152000000.00
2024	414300000.00
2025	8972000000.00

2022	17185000000.00
2023	18248000000.00
2024	19842000000.00
2025	19698000000.00

2022	24248000000.00
2023	22062000000.00
2024	17832000000.00
2025	0.00

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Free Cash Flow (FCF)

$7.42 B
$10.31 B
$10.02 B

-$3.15 B
$414.30 M
$8.97 B

$18.25 B
$19.84 B
$19.70 B

$22.06 B
$17.83 B
-

Y/Y

11.06%

38.86%

2.78%

168.52%

113.14%

2065.58%

6.19%

8.74%

0.73%

9.02%

19.17%

100%

Ratios

Return on Equity (ROE)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Return on Equity (ROE)

24.81%
2.48%
0.00%

48.65%
74.62%
0.00%

51.11%
19.68%
0.00%

46.94%
128.66%
0.00%

Y/Y

14.76%

89.99%

100%

17.03%

53.38%

100%

118.81%

61.51%

100%

31.57%

174.1%

100%

Return on Assets (ROA)

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Return on Assets (ROA)

9.12%
0.81%
0.00%

8.19%
13.45%
0.00%

20.98%
7.81%
0.00%

3.61%
3.17%
0.00%

Y/Y

25.44%

91.08%

100%

35.12%

64.32%

100%

119.11%

62.77%

100%

57.66%

12.32%

100%

Debt to Equity

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Debt to Equity

109.43%
138.18%
108.73%

234.18%
237.06%
160.18%

42.65%
51.24%
58.78%

580.31%
2,040.33%
-2,112.17%

Y/Y

7.87%

26.27%

21.32%

53.58%

1.23%

32.43%

17.37%

20.15%

14.71%

55.98%

251.59%

203.52%

Valuation

Enterprise Value

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Enterprise value

$120.00 B
$131.91 B
$0.00

$546.67 B
$725.64 B
$0.00

$404.57 B
$358.79 B
$0.00

$321.29 B
$376.67 B
$0.00

Y/Y

5.92%

9.92%

100%

51.1%

32.74%

100%

17.17%

11.32%

100%

5.83%

17.24%

100%

Enterprise value to Revenue

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Enterprise value to Revenue

4.43
4.59
0.00

16.02
16.11
0.00

4.75
4.04
0.00

5.92
6.69
0.00

Y/Y

5.35%

3.66%

100%

26.38%

0.56%

100%

22.2%

14.97%

100%

0.64%

13.04%

100%

Enterprise value to EBITDA

Years

2023
2024
2025

2023
2024
2025

2023
2024
2025

2023
2024
2025

Enterprise value to EBITDA

11.43
29.75
0.00

63.81
47.65
0.00

17.35
14.48
0.00

18.71
25.26
0.00

Y/Y

20.66%

160.2%

100%

52.74%

25.31%

100%

5.5%

16.54%

100%

32.56%

35.02%

100%

Gilead Sciences Competitors & Alternatives

Income Statement

Assets & Liabilities | Cash Flow

Profitability

Ratios

Valuation

Related company

Submit feedback to Bullfincher